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Apelin and its G protein-coupled receptor APJ play important roles in blood pressure regulation, body fluid homeostasis, and possibly the
modulation of immune responses. Here, we report that apelin-APJ signaling is essential for embryonic angiogenesis and upregulated during tumor
angiogenesis. A detailed expression analysis demonstrates that both paracrine and autocrine mechanisms mark areas of embryonic and tumor
angiogenesis. Knockdown studies in Xenopus reveal that apelin-APJ signaling is required for intersomitic vessel angiogenesis. Moreover, ectopic
expression of apelin but not vascular endothelial growth factor A (VEGFA) is sufficient to trigger premature angiogenesis. In vitro, apelin is non-
mitogenic for primary human endothelial cells but promotes chemotaxis. Epistasis studies in Xenopus embryos suggest that apelin-APJ signaling
functions downstream of VEGFA. Finally, we show that apelin and APJ expression is highly upregulated in microvascular proliferations of brain
tumors such as malignant gliomas. Thus, our results define apelin and APJ as genes of potential diagnostic value and promising targets for the
development of a new generation of anti-tumor angiogenic drugs.
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Glioblastoma multiforme (GBM) is the most malignant glio-
ma with an invasive and destructive growth pattern. It presents
with increased mitotic activity, tumor necrosis, and pronounced
angiogenesis (Kleihues et al., 2002). Clinically, patients diag-
nosed with GBM show a median survival of less than a year
despite aggressive surgery, radiation, and chemotherapy (Hol-
land, 2001). Current anti-GBM treatment modalities including
radiotherapy plus concomitant and adjuvant temozolomide
(Stupp et al., 2005) provide a modest survival advantage at
best and, hence, alternative therapeutic approaches are urgently
needed.
Tumor angiogenesis is one of the pathological hallmarks of
malignant gliomas (Plate and Risau, 1995), which, in turn,⁎ Corresponding author. Fax: +41 44 633 1358.
E-mail address: brandli@pharma.ethz.ch (A.W. Brändli).
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doi:10.1016/j.ydbio.2007.03.004makes the control of tumor blood supply a promising therapeutic
target. Vascular endothelial growth factors, particularly VEGFA,
are considered to be the most important proangiogenic factors in
pathologic angiogenesis (Ferrara et al., 2003). VEGFA is over-
expressed in most GBMs, and its receptors are present at high
levels on the tumor vessels (Hatva et al., 1995; Plate et al., 1992).
Furthermore, studies using orthotopic animal models indicate
that glioma growth and vascularization is strongly VEGFA de-
pendent and, vice versa, inhibition of VEGFA signaling sig-
nificantly halts glioma growth by blocking neovascularization
and proliferation (Goldbrunner et al., 2000; Goldbrunner et al.,
2004).
Given the importance of VEGFA in tumor angiogenesis,
much attention has focused on developing anti-VEGF or anti-
VEGF receptor (VEGFR) therapies to treat a variety of cancers.
In the last years, various clinical trials have demonstrated the
efficiency of anti-VEGF therapies (Kerbel, 2006). More recent-
ly, however, drug resistance by evasion of VEGF inhibition
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reported to occur in preclinical settings (Casanovas et al., 2005;
Mizukami et al., 2005). Hence, the identification and develop-
ment of alternative drug targets to prolong the effectiveness of
antiangiogenic drugs is pertinent.
APJ (putative receptor protein related to the angiotensin re-
ceptor AT1; angiotensin II related receptor-like 1—Agtrl1) and
its amphibian orthologue Msr encode members of the G protein-
coupled receptor (GPCR) gene family that have been implicated
in the control of blood vessel development (Devic et al., 1996;
Devic et al., 1999). Originally identified as orphan GPCRs, APJ
and Msr are structurally related to the angiotensin II receptor
type I (AT1R) (Devic et al., 1996; O'Dowd et al., 1993) but
despite the significant structural homology, angiotensin II does
not bind to APJ (Tatemoto et al., 1998). Apelin, the natural
ligand of APJ was isolated from bovine stomach (Tatemoto et
al., 1998). In mammals, the apelin gene encodes a secreted
preprotein of 77 amino acids with a signal peptide, a prodomain,
and a C-terminal peptide, which upon proteolytic maturation
generates a number of apelin polypeptides (Tatemoto et al.,
1998). Apelin-36, comprised of amino acids 42–77, and apelin-
13 (amino acids 65–77) represent the predominant and most
active isoforms (Hosoya et al., 2000; Tatemoto et al., 1998). In
the adult, apelin and its receptor are expressed both in the brain
and in the periphery, particularly in the gastrointestinal tract,
adipose tissues, lung, kidney, liver, and the skeletal muscle. In
addition, APJ and apelin are highly expressed in the cardio-
vascular system, where they play important physiological roles
in the regulation of blood pressure and cardiac contractility
(Kleinz and Davenport, 2005; Masri et al., 2005). During
postnatal development, apelin signaling is also associated with
retinal blood vessels, where it may function to regulate angio-
genesis (Kasai et al., 2004; Saint-Geniez et al., 2002). The role
of apelin-APJ signaling in embryonic angiogenesis and its sig-
nificance for pathologic angiogenesis has, however, remained
largely elusive. While this manuscript was in preparation, two
studies reporting contradicting results about the role of apelin
signaling during cardiovascular development in the Xenopus
embryo were published (Cox et al., 2006; Inui et al., 2006). Cox
et al. demonstrate that apelin and APJ play important roles in
blood vessel morphogenesis, where they are required for the
formation of intersomitic vessels. In contrast, the study of Inui
et al. suggests that apelin and APJ play more general roles in
cardiovascular development by regulating differentiation of
endothelia, hematopoietic cells, and cardiomyocytes.
Here we provide novel mechanistic insights into the role of
apelin-APJ signaling during blood vessel formation under nor-
mal and pathological conditions. Apelin expression is asso-
ciated with angiogenic blood vessel growth, where it acts via
paracrine and autocrine mechanisms. We demonstrate that
apelin-APJ signaling is necessary and sufficient to promote
angiogenic blood vessel growth in vivo. Interestingly, we failed
to observe in our loss-of-function studies any evidence of gene-
ral defects in cardiovascular development supporting the view
of a primary role of apelin signaling in angiogenesis. Epistasis
analysis in Xenopus embryos suggests that apelin signaling
functions downstream of VEGFA. Finally, we provide evidencefor an important role of apelin and APJ in tumor angiogenesis,
namely to pathological vessel formation in GBM. Taken
together, our studies identify apelin and its receptor APJ as
novel targets for anti-angiogenic tumor therapies.
Materials and methods
Cloning of cDNAs, sequencing, and sequence analysis
Expressed sequence tag (EST) databases were screened for potential Xe-
nopus laevis cDNAs related to human apelin, APJ and VEGFA. For each gene,
multiple cDNAs were identified and retrieved. Sequence comparisons revealed
that each human gene was represented by two classes of cDNAs, which are
likely to be derived from two pseudoallelic gene variants present in the X. laevis
genome. Xenopus cDNAs for apelin-a (GenBank Acc. No. BE680255), APJa
(AW460831),APJb (BQ399449,BQ724849,BQ726502),VEGFAb(BF426570)
were obtained from the RZPD German Resource Center for Genome Research.
Xenopus cDNAs for apelin-b (BJ030743) and APJb (BJ033869) were kindly
provided by the NIBB X. laevis EST Project, Japan. Double-stranded DNA
sequencing was either performed in-house or by Primm srl, Italy. Assembly of
nucleotide sequence traces, analysis of nucleotide and protein sequences was
performed using the DNAStar Lasergene software package (version 6.0).
Amino acid sequence alignments were performed with MegAlign (DNAStar)
using the Clustal W algorithm and the PAM250 residue weight table. The
alignments then were used to construct phylogenetic trees with the Neighbor-
Joining algorithm (Saitou and Nei, 1987). The described Xenopus nucleotide
sequences were deposited with GenBank: apelin-a (GenBank Acc. No.
DQ471852), apelin-b (DQ471853), APJa (DQ473441), APJb (DQ473442),
and VEGFAb168 (DQ481238).
Plasmid constructs
The following constructs were generated for in vitro coupled transcription–
translation reactions and/or in vitro RNA synthesis. Plasmid Apelin-ORF con-
tains the ORF of Xenopus apelin-a (Gene Bank Acc. No. DQ471852). Plasmid
Apelin-(5′)-UTR encodes 18 nucleotides of the 5′UTR followed by the ORF of
apelin-a. Plasmid Apelin (F13A) contains the complete ORF of apelin-a but the
carboxy-terminal phenylalanine was substituted by alanine. Plasmid APJa-ORF
contains the ORF plus 118 nucleotides of the 3′UTR of Xenopus APJa
(DQ473441). Plasmid APJa-(5′)-UTR contains 36 nucleotides of the 5′UTR and
the ORF of APJa. Plasmid APJb-ORF contains 43 nucleotides of the 5′UTR, the
ORF, and 89 nucleotides of the 3′UTR of Xenopus APJb (DQ473442). Plasmid
VEGFA-ORF contains the ORF of Xenopus VEGFAb (isoform 4, VEGFA168,
DQ481238). Plasmid VEGFA-MIS contains essentially the ORF of Xenopus
VEGFAb (DQ481238), but seven point mutations were introduced which
encode the original amino acid sequence but no longer serve as a target for the
VEGFA-MO (see below). All plasmids were generated by PCR using the
Expand High Fidelity PCR System (Roche Diagnostics) and subcloned into the
pCS2+ vector (Turner and Weintraub, 1994). The constructs were confirmed by
DNA sequencing.
Xenopus embryo manipulations, in situ hybridization, and sectioning
In vitro fertilization, culture and staging of Xenopus embryo were performed
as described (Brändli and Kirschner, 1995; Helbling et al., 1998). Probe synthe-
sis, whole mount in situ hybridization, β-galactosidase staining, and bleaching
of Xenopus embryos were carried out as described (Helbling et al., 1999;
Helbling et al., 1998; Saulnier et al., 2002). In some cases, embryos were
immersed into clearing solution (2:1 benzyl benzoate/benzyl alcohol) to vi-
sualize staining of internal structures. Digoxigenin-labeled probes were synthe-
sized from linearized plasmids encoding Xenopus Msr (Devic et al., 1996),
APJb (GenBank Acc. No. DQ473442), apelin-a (DQ471852), Erg (Baltzinger et
al., 1999), Fli1 (Meyer et al., 1995), VEGFR2 (BJ075253), VEGFR1 (BQ736
324), Gata3 (Bertwistle et al., 1996), αT3-globin (Banville and Williams, 1985),
Pecam1 (BF612503), and Tie2 (Iraha et al., 2002). Sense strand controls were
prepared from all plasmids and tested negative by in situ hybridization.
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melt agarose for sectioning with a vibrating blade microtome (Leica VT1000S)
as described previously (Eid and Brändli, 2001). Pictures were taken using either
bright-field or Normarski optics.
Microinjection of Xenopus embryos
The following morpholino oligonucleotides (MO) were ordered from Gene
Tools LLC (Corvallis, OR) to inhibit translation of Xenopus mRNAs (initiation
codons are underlined; mispaired nucleotides are indicated with small letters):
Apelin-MO, 5′-GTCTGAGATTCATGTTTCTTGTGGC-3′ (which targets ape-
lin-a and apelin-b); Apelin-MO(mp), 5′-GTCTGtGATTgATGTaTCTTcTGGC-
3′; APJ-MO, 5′-CTGTGTGGAAGCAATAGAAAGTCCT-3′ (which targets the
5′UTR of APJ-a and APJ-b); APJ-MO(mp), 5′-TGaGTGcAAGCtATA-
GAAtGTCCT-3′, VEGFA-MO, 5′-GATCCAGCTCGGCAGAAAGTTCATG-
3′ (which targets both VEGFAa and VEGFAb); VEGFA-MO(mp), 5′-GATg-
CAGgTCcGCAcAAAGTTgATG-3′. In vitro coupled transcription–translation
reactions and MO injections were performed as described (Saulnier et al.,
2002). If not indicated differently, 0.1 to 10 ng of each MO were injected per
single blastomeres of two-cell-stage embryos. RNA synthesis and microinjec-
tions were performed as described (Helbling et al., 1998) except that
purification was done by phenol–chloroform extraction. For rescue experi-
ments, mRNA was synthesized using plasmid Apelin-ORF as a template. In
some experiments, mRNA injections were performed into V2 or D2 blasto-
meres of 8-cell stage embryos (Moody and Kline, 1990). RNA encoding the
lineage tracer nuclear β-galactosidase (nucβgal) was usually coinjected at 0.25
ng per blastomere.
Whole mount in situ hybridization of mouse embryos
Mouse embryos were obtained from matings of NMRI wildtype animals.
For timed pregnancies plugs were checked in the morning after mating, noon
was taken as 0.5 days post coitum (d.p.c.). Embryos were fixed in 4% PFA and
stored in 100% methanol at −20 °C prior to in situ hybridization analysis.
Whole-mount in situ hybridization on mouse embryos was essentially per-
formed following a standard procedure (Wilkinson, 1992). Digoxigenin-labeled
probes were transcribed from linearized plasmids encoding mouse APJ (Gen-
Bank Acc. No. AA098426) and apelin (BG176301). Stained specimens were
transferred into 80% glycerol for documentation.
Establishment of CHO cells stably expressing Xenopus APJ-EGFP
Flp-In-CHO-K1 cells (R75807; Invitrogen) were used to create a cell line
stably expressing the XenopusAPJ-EGFP fusion protein under the control of the
human cytomegalovirus immediate-early enhancer/promotor. The full open
reading frame (ORF) of X. laevis Msr/APJa (Devic et al., 1996) was amplified
by PCR and subcloned in-frame into the XhoI and HindIII sites of pEGFP-N1
vector (#U55762; BD Biosciences). The resulting plasmid was digested with
NheI and NotI and the APJ-EGFP cDNA was subcloned into pcDNA5/FRT
vector (Invitrogen) to generate the Flp-In expression vector pcDNA5/FRT/APJ-
EGFP. Cotransfections of pcDNA5/FRT/APJ-EGFP and pOG44 into Flip-In-
CHO-K1 cells were done using the FuGENE6 transfection reagent (Roche) and
selections were performed according to the manufacturer's instructions.
Transfected cells were evaluated by fluorescence microscopy for APJ-EGFP
expression at the cell surface. The resulting Flp-In-CHO-APJ-EGFP (in short:
CHO-APJ) cell line was grown at 37 °C in DMEM growth medium (DMEM
containing 10% FCS and 1% penicillin–streptomycin solution; GIBCO/
Invitrogen) under standard techniques.
Internalization assays
CHO-APJ cells were diluted in DMEM growth medium and seeded (200 μl/
well) on 8-well glass slides (Lab-Tek Chamber Slides, Nunc). The cells were
cultured overnight at 37 °C to 70–90% confluency. Apelin-13 (pyroglutamy-
lated apelin-13; # H-4568, Bachem) and angiotensin II (#H-1705, Bachem) were
dissolved at different concentrations (0.1, 0.2, 0.5 and 1 μM) in DMEM
containing 1% BSA. To initiate the assay, the cells were washed with 0.5 ml PBSand treated with apelin-13 or angiotensin II peptides in DMEM/1% BSA for 0,
30, 60 or 120 min at 37 °C. Cells were washed with PBS at 4 °C and fixed in
fixation buffer (4% paraformaldehyde in PBS) for 15 min. Cells were washed
with 0.1 M glycine in PBS, and then with PBS. To stain nuclei, cells were
incubated with 3 μg/ml DAPI in PBS for 1 min and washed with PBS. Samples
were mounted in Citifluor AF-1 mounting medium (Citifluor Ltd.). Cells were
examined under a fluorescent microscope (Axioskop, Zeiss) and pictures were
taken using a confocal laser scanning microscope (CLSM 410, Zeiss). Picture
stacks were processed on a silicon graphics workstation using Imaris software
(Bitplane).
cAMP assays
CHO-APJ cells were seeded into black 96-well plates (Costar) at a density of
65,000 cells/cm2 and grown for 1 day. The growth medium was replaced by PBS
containing 0.2 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma) to initiate the
assay. After 45 min, an equal volume of PBS containing 0.2 mM IBMX, 2 μM
forskolin (Sigma) and apelin-13 (final concentration ranging from 0 to 8 μM)
was added. After 30 min at 37 °C, the cAMP levels were measured with the
cAMP Fluorescence Polarization Biotrak Immunoassay System (Amersham)
using a fluorescence plate reader (GENios Pro, Tecan). The fluorescence
polarization was measured according to the manufacturer's recommendation.
CHO-APJ treated with forskolin alone served as reference. The parental Flip-In-
CHO-K1 cells, which do not express APJ, were used as a background control.
The inhibition of cAMP production was calculated as mean±standard deviation
of triplicate assays.
Human endothelial cell culture
Culture media and primary human endothelial cells (umbilical vein
endothelial cells, HUVEC, #CC-2519; umbilical arterial endothelial cells,
HUAEC, #CC-2520; dermal microvascular endothelial cells, HMVEC-D, #CC-
2516) were obtained from Cambrex. Endothelial cells were cultured either in
EGM-2 (for HUVEC) or EGM-2-MV (HUAEC, HMVEC-D) according to the
supplier's recommendations. The cells were used up to passage 5.
RT-PCR assays
For standard RT-PCR, total RNAwas extracted from HUVEC and HUAEC
cultures (90% confluency) with TRIzol reagent (Invitrogen) according to the
manufacturer's instructions. Traces of genomic DNA were removed by
treatment with Dnase I (Roche). RNA was purified by phenol/chloroform
extraction and precipitated with isopropanol. RT-PCR was performed with the
Superscript One-Step RT-PCR Kit with Platinum Taq (Invitrogen). The primer
sequences for each human target gene were as follows: apelin, sense (5′-GGG
GGA AGC AGG CAG TGA GAA G-3′) and antisense (5′-GAA TGG GCT
GGA AGCGGC AAT GT-3′); APJ, sense (5′-CTG GCT GTA GGGGAT GGA
TTT CTC-3′) and antisense (5′-CAC CGG GGA CTT GGA GAA CAC C-3′);
and GAPDH, sense (5′-CAT GTG GGC CAT GAG GTC CAC CAC-3′) and
antisense (5′-TGA AGG TCG GAG TCA ACG GAT TTG GT-3′). The reverse
transcription was carried out at 50 °C for 30 min using 500 ng of total RNA. The
PCR conditions were as follows: denaturation at 94 °C for 15 s, annealing at
58.9 °C for human APJ and human GAPDH and 61.1 °C for human apelin for
30 s and extension at 72 °C for 2 min. 40 cycles were carried out followed by an
extension step at 70 °C for 7 min. The expected amplification products of 300,
600 and 960 bp for apelin, APJ, and GAPDH, respectively were examined on a
2% agarose gel.
For quantitative real-time PCR, total RNAwas prepared from HUVEC (3rd
passage) and HUAEC (5th passage) using the RNeasy Mini Kit (Qiagen). First
strand cDNAs were synthesized using random hexamer primers and TaqMan
Reverse Transcription Reagents (Applied Biosystems). For each cell type,
100 ng cDNAwas analyzed by real-time PCR using the following TaqMan Gene
Expression Assays (Applied Biosystems): Apelin (Assay ID: Hs00936329_m1),
APJ (Hs00945496_s1), and GAPDH (Hs99999905_m1). TaqMan PCR was
done with an ABI 7900HT Real-Time PCR System (Applied Biosystems). The
relative expression levels of apelin and APJ were normalized to the amount of
the house keeping gene GAPDH in the same cDNA preparation.
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A colorimetric method measuring conversion of the MTS tetrazolium com-
pound to a water-soluble formazon dye, which is proportional to the number of
metabolically active cells, was used to assay cell proliferation (Cory et al.,
1991). Primary endothelial cells were seeded into 96-well plates (1500 cells/
well) in 150 μl minimal medium (EBM-2, Cambrex; 1% FCS, GIBCO; 0.1%
BSA) containing 50 μg/ml gentamicin. After overnight incubation at 37 °C, the
medium was supplemented with VEGF165, bFGF or apelin-13. VEGF and
bFGF were used at their optimal concentration of 1 and 10 ng/ml, respectively,
as determined in pilot experiments (data not shown). Apelin-13 was used in
concentrations ranging from 0.1 to 100 nM. Fresh minimal medium containing
the growth factors was added every 24 h. Control wells were treated identically
using minimal medium without growth factors. After 72 h, cell proliferation was
measured using a tetrazolium compound-based [3-(4,5-dimethyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS]
assay (CellTiter 96 AQ One Solution Cell Proliferation Assay; Promega)
according to the manufacturers instructions. The colorimetric method deter-
mines the number of viable, metabolically active cells in culture. 490-nm ab-
sorbance was measured using a VersaMax microplate reader (Molecular
Devices). Background absorbance from wells containing no cells was subtracted
from all measurements and six replicate samples were used to calculate the mean
(±standard deviation) in each experiment.
Chemotaxis assays
The chemotactic response of HUVECs was assayed using a 48-well
chemotaxis chamber (Neuro Probe, Inc.). Polycarbonate membranes (8-μm pore
size; Neuro Probe) were precoated overnight with a 0.1% gelatin solution. Cells
were (8×105 cells/ml) in minimal medium (EBM-2, 0.1% BSA). Minimal
medium without additional factors or containing VEGFA165 (#354107, BD
Biosciences), bFGF (#354060, BD Biosciences), apelin-13, or angiotensin II
was placed in the lower chambers. 100 μl of cell suspension was added to the
upper chamber. After 4 h at 37 °C, non-migrating cells were removed from the
upper surface of the membrane and migrated cells on the lower surface were
fixed with 100% methanol containing 1 μg/ml DAPI. The stained cells were
observed with a fluorescence microscope and digital images of at least seven
different fields of the membrane were analyzed using NIH image 1.63 software
to assess the number of cells that had migrated. The data shown represent the
mean (with a 95% confidence interval) of six independent experiments.
Endothelial spheroid sprouting assay
Endothelial spheroids comprised of 1200 cells were generated as described
(Korff and Augustin, 1998). Typically, 40 spheroids were resuspended in 1 ml of
a rat tail collagen solution (#1179179, Roche) containing either buffer only,
10 ng/ml VEGF, or 100 nM apelin-13. After 48 h, the number of sprouts per
spheroid was quantified using an inverted microscope (Zeiss Axiovert S100
TV).
Analysis of tumor specimens
Formalin-fixed and paraffin-embedded biopsy samples of glioblastoma
multiforme (GBM; n=24, patients ranging from 37 to 81 years, three of them
with an oligodendroglial component) and a control CNS specimen were ob-
tained from the Institute of Neuropathology, University Hospital Zurich,
Switzerland. The study was conducted according to the standard regulations of
the local ethical committee. The diagnoses of GBM were made in line with the
World Health Organization (WHO) classification of brain tumors (Kleihues et
al., 2002), and all samples were re-evaluated by FLH. GBMs are defined as
malignant astrocytomas displaying tumor necroses and/or microvascular pro-
liferation, and correspond to a WHO grade IV.
Specimens were automatically processed on a Ventana Discovery instrument
(Ventana Medical Systems) according to the manufacturer's instructions (Nitta
et al., 2003). Briefly, paraffin sections were automatically deparaffinized, fixed,
cooked in Tris buffer (pH 6.0) for 60 min and subjected to protease digestion.
Hybridizations were performed with digoxigenin-labeled probes (for PECAM1and VEGF, 5 ng/slide; apelin and APJ, 50 ng/slide) for 6 h, and the signal was
detected using a Nitro blue Tetrazolium chloride 5-Bromo-4-cloro-3-indolyl
phosphate toluidine salt (NBT/BCLIP) substrate solution for 3 h on the instru-
ment. Digoxigenin-labeled antisense probes were generated from the following
plasmids: human APJ (GenBank Acc. No. BI548627), APELIN (BM811482),
PECAM1 (BQ067751), and VEGFA (BU153227). Sense probes only exhibit
unspecific background signals (not shown).
Photography and computer graphics
Images of cultured cells or sectioned embryos were captured with an Axio-
Cam Colour camera mounted on an Axioscop 2 MOT light microscope (Zeiss)
and for whole mount embryo images using a Stemi 2000 stereoscopic micro-
scope (Zeiss). Composite figures were organized and labeled using Adobe
Photoshop CS and Adobe Illustrator CS software.
Results
Cloning of Xenopus apelin and APJ cDNAs
We identified two classes of apelin cDNAs, which are de-
rived from two distinct apelin genes, apelin-a and apelin-b,
present in the pseudotetraploid X. laevis genome (Supplemen-
tary Fig. 1). The two genes encode identical polypeptides of 76
amino acids and thus will be referred to as Xenopus apelin.
Interestingly, the highest degree of amino acid conservation
between Xenopus and mammals is localized to the C-terminus
with a stretch of 14 identical residues harboring apelin-13, the
most bioactive apelin peptide (Fig. 1A, Supplementary Fig. 1).
We also identified two distinct classes of transcripts encoding
Xenopus homologues of the apelin receptor APJ, which repre-
sent pseudoallelic orthologues and will be referred to as Xeno-
pus APJa and APJb (Supplementary Fig. 2). Noteworthy, the
Xenopus APJa protein is largely identical to the previously
reported Xenopus Msr protein (Devic et al., 1996), but the two
sequences differ with regard to their C-termini due to a single
nucleotide insertion in the Msr sequence (Supplementary Fig.
2). The C-termini of the X. laevis APJ proteins reported here are
identical with the Xenopus tropicalis APJ protein (GenBank
Acc. No. NM_001032321).
Apelin expression preceeds intersomitic vein angiogenesis
The vascular expression patterns of Xenopus APJa (not
shown) and APJb (Figs. 1B–E) were identical, in line with the
previous report by Devic et al. (1996). Interestingly, apelin ex-
pression was strongly upregulated in mesenchymal tissues,
which were in close proximity to subsets of newly forming
blood vessels (Figs. 1F, G; Supplementary Fig. 3). Particularly,
the development of intersomitic vessels, which are the first
blood vessels of the embryo to form by sprouting angiogenesis
(Poole and Coffin, 1989), was associated with apelin expression
(Figs. 1F–I). In Xenopus, intersomitic vein (ISV) formation
along the anteroposterior body axis occurs in a recurring pattern
(Helbling et al., 2000; Millard, 1949). Most strikingly, expres-
sion of apelin was detected in cell populations of the dermatome
flanking the intersomitic space between trunk somites 2 and 3
(Fig. 1G). Subsequently, dermatomal apelin expression ap-
peared successively in more posterior trunk somites and expres-
Fig. 1. Apelin expression precedes angiogenic growth of intersomitic vessels. (A) Apelin-13 is conserved from Xenopus to man. The amino acid sequences were
aligned using ClustalW. Invariant residues are shaded black. The conserved, mature apelin-13 peptide is underlined. The predicted sites for signal peptide cleavage
(arrow) and proprotein processing (arrowheads) generating apelin-36, apelin-17 and apelin-13 are indicated. (B–S) The expression patterns of apelin and APJ during
Xenopus embryogenesis (B–O) and in the mouse embryo (P–S) were determined by whole mount in situ hybridization. Sections of the trunk (N, O) were cut
horizontally at the level of the somites. (B) APJ is detected in all blood vessels including the PCV (arrow), the ISVs (arrowheads) and the VVN (asterisk). (C) APJ is
present in the PCV (arrow). (D) Various ISVs (arrowheads) expressing APJ can be detected. (E) APJ levels remain high in all vessels including the ISVs (arrowhead),
lateral capillaries (open arrowheads) and the PCV (arrow). (F) Apelin transcripts are found in areas of angiogenesis, such as the intersomitic spaces (arrowheads) but
not ventrally (asterisk), where the VVN is forming by vasculogenesis (compare with panel B). (G) In the dermatome (arrowhead), apelin marks the intersomitic spaces,
where ISVs will start to sprout. (H) Apelin mRNA is found in areas, where newly forming ISVs are detected (arrowheads). Most notably, a further, posterior domain
(arrow) expresses apelin, while no ISV has emerged yet (compare with panel D). (I) Apelin stains the dorsal neural tube (arrowhead) and lateral capillaries (arrows)
sprouting into the somites. (J) VEGFA is expressed in all somites (bracket) and the pronephric glomerulus (arrowhead). (K, L) Somitic VEGFA expression remains
unaltered during intersomitic vessel growth. (M) Downregulation of VEGFA as ISV formation is completed. (N) APJ staining is confined to the ISVs (arrowheads).
(O) Apelin stains the dermatome flanking the intersomitic spaces (arrows). The most mature ISVs express apelin (arrowhead), while the others are still negative (open
arrowheads). (P) APJ is expressed throughout the developing vasculature including intersomitic vessels (arrowheads). (Q) Apelin expression is restricted to tissue
undergoing angiogenesis, such as the tail (arrowhead) and limb buds (asterisks). (R) Tail explant, where APJ expression is detected in all intersomitic vessels
(arrowhead). (S) Apelin stains intersomitic vessels, particularly in the leading edges (arrowheads).
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Figs. 1C–E with G–I). As revealed by sectioning, intersomitic
veins start expressing apelin as they extend (Figs. 1N, O). This
suggests that apelin acts initially in a paracrine manner and
subsequently in an autocrine fashion to stimulate APJ signaling
in intersomitic endothelia. Apelin expression is also associatedwith mesenchymal tissues in other areas of angiogenic blood
vessel growth, such as the head, the visceral arches, and the
dorsal midline (Fig. 1F; Supplementary Fig. 3). Expression is,
however, notably absent from the vitelline vein network (VVN),
which is generated by vasculogenic mechanisms (Figs. 1B, F).
In mouse embryos, high levels of APJ expression were detected
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loping limbs (Figs. 1P, R; Supplementary Fig. 4), in line with
earlier reports (Devic et al., 1999; Saint-Geniez et al., 2002). In
contrast, apelin expression was restricted to areas of ongoing
angiogenesis, such as intersomitic spaces, the dorsal midline,
and limb buds (Figs. 1P, S; Supplementary Fig. 4). Hence,
apelin and APJ expression during angiogenesis is conserved
between vertebrates.
Apelin signaling is induced during tumor angiogenesis
We next asked whether apelin and APJ are expressed in
human brain tumors presenting with extensive vessel formation.
To date, 24 glioblastoma multiforme (GBM) specimens were
analyzed (Fig. 2). GBM is typically composed of poorly differ-
entiated neoplastic astrocytes and characterized by increased
cell proliferation, tumor necrosis, and extensive angiogenesis
(Kleihues et al., 2002). Expression of the endothelial marker
PECAM1 (CD31) identified intraparenchymal and meningeal
vessels within normal tissue of the central nervous system (Fig.Fig. 2. Apelin and APJ are upregulated in GBM specimens. Sections of GBM specime
used for in situ hybridization. Close-up views of the boxed areas are shown below
200 μm (A–J), 100 μm (close-up views). (A) H&E staining of GBM specimen. (B) G
for PECAM1 expression. (C) Radially orientated neoplastic cells surrounding band-li
in microvascular proliferations (arrows). (D) High-level of APELIN expression is d
radially orientated neoplastic cells surrounding band-like necroses (asterisks). (E) A
within neoplastic cells accumulating next to band-like necroses (asterisks). (F) H&
intraparenchymal vessels (not shown) within normal CNS tissue display PECAM1 sig
normal CNS tissues. (J) Moderate APJ staining (arrows) is present in meningeal ve2G). Microvascular proliferations, sometimes presenting as
multilayered ‘glomeroid tuft’ within GBM specimens, appeared
to display a stronger PECAM1 signal when compared to normal
controls (Fig. 2B). While VEGFA and apelin were undetectable
in normal brain vessels, APJ exhibited low-level RNA expres-
sion (Figs. 2H–J). However, APJ and apelin transcripts were
consistently highly upregulated within microvascular prolifera-
tions in GBM specimens (n=24; Figs. 2D, E). In addition,
apelin and APJ transcripts (Figs. 2C–E) – albeit less pro-
nounced when compared to microvascular proliferations – were
preferentially expressed in radially orientated neoplastic cells
surrounding band-like or serpiginous necrotic foci (“pseudopa-
lisading necroses”). These observations are reminiscent of
PDGF and VEGF expression patterns, as previously described
(Hermanson et al., 1992; Plate and Risau, 1995).
Apelin signaling is required for intersomitic vein angiogenesis
We performed loss-of-function studies in Xenopus embryos
using morpholino antisense oligonucleotides (MO) to assess thens and of normal CNS tissue were stained with hematoxylin and eosin (H&E) or
each panel. Pseudopalisading necroses are indicated with asterisks. Scale bars:
lomeruloid tuft-like microvascular proliferations (arrows) of GBM are positive
ke necroses (asterisks) express VEGFA. Baseline VEGFA expression is also seen
etected within microvascular proliferations (arrows) and, to some extent, within
PJ is upregulated within microvascular proliferations (arrows) and occasionally
E staining of normal CNS tissue specimen. (G) Meningeal (arrows) as well as
nals. (H, I) VEGFA (H) and APELIN (I) expression is undetectable in vessels of
ssels of normal CNS tissue.
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Special care was taken to select MOs, which target transcripts of
both pseudoallelic genes (Supplementary Figs. 1 and 2). Fur-
thermore, mispaired MOs were used as specificity controls. The
MOs inhibited protein synthesis in cell-free coupled transcrip-
tion–translation assays (Supplementary Fig. 5).
MO-injected embryos were analyzed by in situ hybridization
using a collection of tissue-specific molecular markers to
visualize the developing vasculature (Fig. 3A, Supplementary
Fig. 6; data not shown for Tie2, VEGFR1, VEGFR2). Neither
injection of apelin-MO nor APJ-MO resulted in alteration of theFig. 3. Apelin-APJ signaling is necessary and sufficient for ISVangiogenesis. MO oli
tracer nuclear β-gal were co-injected into single blastomeres. Injected embryos were
β-gal activity. Expression of marker geneswas visualized by in situ hybridization. Scal
required for ISV angiogenesis. Arrowheads indicate the intersomitic spaces, which
unaffected. (C) Apelin is sufficient to induce premature angiogenesis of ISVs. Single
On the injected side, all intersomitic spaces including the posterior ones (white arrowh
the control side is largely devoid of ISVs. (D) Co-injection of apelin mRNA rescues
injected unilaterally into single blastomeres of 2-cell stage embryos. ISVs were visuali
were determined.general expression levels and domains of apelin (Supplemen-
tary Fig. 6) and APJ (not shown). This indicates that the ex-
pression of apelin and APJ is not subject to autoregulation.
Marker gene analysis of MO-injected embryos indicated that
development of erythrocytes, pronephric kidneys, somites, and
the nervous system was unperturbed (Supplementary Fig. 6; not
shown). The assembly of the primary vascular plexus consisting
of the VVN and associated major vessels such as the posterior
cardinal veins (PCV) appeared unaffected (Fig. 3A; Supple-
mentary Fig. 6). We therefore conclude that apelin-APJ sig-
naling is not required for vasculogenesis.gonucleotides (5 ng) or apelin mRNA (1 ng) and mRNA (0.25 ng) for the lineage
raised to stage 32 (C), 35/36 (A, B) or stage 37/38 (D), fixed, and processed for
e bars: 400 μm, embryo views; 200 μm, close-up views. (A, B) APJ and apelin are
are devoid of ISVs. Note that the PCV (arrow) and the VVN (asterisk) remain
V2 blastomeres of 8-cell-stage embryos were injected with apelin mRNA (1 ng).
eads) are occupied by ISVs, which had formed prematurely. Note that at stage 32,
the apelin-MO phenotype. The indicated amounts of MOs and/or mRNAwere
zed in situ hybridization, and the frequencies of embryos with severe ISV defects
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foundly affected by MO injections (Figs. 3A, B; Table 1). ISV
growth was impaired by injection of either apelin-MOs or APJ-
MOs. Similarly, co-injection of both apelin- and APJ-MOs
caused ISV phenotypes. Rescue experiments revealed substan-
tial, dose-dependent restoration of the ISV growth by prepro-
apelin mRNA (Fig. 3D). In an alternative approach, we also
evaluated whether a recently described apelin-specific antago-
nist (Lee et al., 2005), apelin-13 (F13A), would interfere with
ISV formation in vivo. In contrast to apelin-MO knockdowns,
injections of Xenopus apelin-13 (F13A) mRNA failed to disrupt
ISV formation in a dominant manner (not shown). Our findings
support previous studies indicating that apelin-13(F13A) does
not act in an antagonistic manner (Fan et al., 2003; Medhurst et
al., 2003). Taken together, the MO knockdown experiments
demonstrate that both apelin and its receptor APJ are
dispensable for vasculogenesis but are required for angiogenesis
of ISVs.
Apelin is sufficient to induce premature intersomitic vein
angiogenesis
As shown in Fig. 1, the expression of apelin is temporally
and spatially highly regulated and precedes the initiation of ISV
growth. We therefore asked whether premature, ectopic expres-
sion of apelin in the developing somites would have an effect on
intersomitic vessel formation. Injections of apelin mRNAwere
performed unilaterally into single V2 blastomeres at the 8-cell
stage. The injected embryos were raised until stage 32, when the
control sides showed evidence for the initiation of the most
anterior ISVs (Fig. 3C). By contrast, injection of apelin induced
fully extended ISVs. This phenotype was observed by using
different molecular markers, such as Erg (Fig. 3C), VEGFR2
and Pecam1 (not shown) in repeated experiments (N=4), and
occurred on average in about 57% of the apelin-injected em-
bryos (range 42–82%; n=110). Remarkably, there was no evi-
dence for mistargeting of the prematurely formed ISVs indi-
cating that EphB4-mediated repulsive signaling (Helbling et al.,
2000) was fully functioning. Overexpression experiments withTable 1
Summary of intersomitic vein defects in MO-injected Xenopus embryos









Apelin-MO 5 49 239
Apelin(mp)-MO 5 2 175
APJ-MO 5 56 276
APJ(mp)-MO 5 9 139
Apelin-MO and 5 63 95
APJ-MO 5
MO injections were performed unilaterally into single blastomeres at the two
cell-stage. At stage 35/36, embryos were processed for whole mount in situ
hybridization. The vascular marker Erg was used to visualize ISVs. The em-
bryos were scored for strongly reduced and/or absent ISVs. For each MO, two to
eight independent experiments were performed. Similar results were obtained
with embryos stained for the vascular markers VEGFR2 and APJ. ISV, inter-
somitic vein; MO, morpholino; mp, mispaired control.APJ mRNA did not result in abnormal or premature vascular
development (not shown). We conclude that ectopic apelin
expression alone is sufficient to induce premature angiogenesis
of ISVs in Xenopus.
VEGFA is not sufficient to trigger premature intersomitic vein
angiogenesis
To explore the epistatic relationship between VEGFA and
apelin signaling in ISV angiogenesis, we first compared the
temporal and spatial expression of VEGFA to apelin. We iden-
tified a novel Xenopus VEGFA isoform, VEGFAb168, which is
equivalent to human VEGFA165, transcript variant 4 (Supple-
mentary Fig. 7). Xenopus VEGFAb168 is derived from a se-
cond pseudoallelic X. laevis VEGFA gene, VEGFA-b. The two
Xenopus VEGFA genes are expressed in an identical fashion.
Somitic expression of VEGFA is detected as early as stage 23
(Cleaver et al., 1997) prior to apelin expression, which is only
detectable from stage 29/30 onwards (Figs. 1G, K). Importantly,
VEGFA expression is present simultaneously in all developing
somites and is gradually downregulated at stage 37/38 (Figs.
1J–M). On the contrary, apelin expression is intimately corre-
lated with the appearance of ISVs along the anteroposterior
body axis (Figs. 1F–I).
To assess whether apelin and APJ expression requires
VEGFA signaling, we injected VEGFA-MOs (Supplementary
Fig. 7). Knockdown of VEGFA caused severe vascular abnor-
malities including absence of ISVs, defects in PCV assembly,
and development of an immature, hypoplastic VVN (Fig. 4A;
Supplementary Fig. 5; Table 2). This indicates that VEGFA is
required for vasculogenesis in Xenopus. Interestingly, expres-
sion of APJ and apelin was unaffected in VEGFA-MO injected
embryos (not shown). This suggests that VEGFA signaling does
not initiate vascular APJ and somitic apelin expression.
Unilateral injections of VEGFA mRNA failed to promote
premature outgrowth of ISVs, but caused severe disorganization
of the VVN (Fig. 4B). The characteristic, highly elaborate VVN
pattern (Fig. 4A, control side) had collapsed into a disorganized
and hyperplastic structure, where distinct vessels were no longer
discernable. This VVN phenotype is clearly different from the
one seen in VEGFA knockdown embryos (compare Figs. 4A,
B). Notably, we frequently observed the VVN phenotype bila-
terally indicating that the injected VEGFA mRNA acted at long
range (Fig. 4B). Unlike control embryos, most hyperplastic
VVNs of the VEGFA-injected embryos (85%, n=39) expressed
apelin ectopically (Figs. 4C, H). Hence, in contrast to apelin,
VEGFA was not sufficient to promote premature ISV angio-
genesis. VEGFA overexpression was, however, sufficient to
induce ectopic apelin expression in the VVN. Since VEGFA is
not required for apelin expression, multiple signaling pathways
may act along side of VEGFA to induce and/or maintain apelin
expression.
VEGFA acts upstream of apelin in vascular development
We performed combinations of gain- and loss-of-function
experiments to further explore the epistatic relationship of
Fig. 4. VEGFA acts upstream of apelin signaling in vascular development. MO oligonucleotides and/or mRNAwere co-injected unilaterally into single D2 (A, B, D, F)
or V2 (C, E, G, H) blastomeres of 8-cell stage embryos. Injected embryos were raised to stage 35/36 and processed in situ hybridization. (A) The vascular defects in
VEGFA-MO (5 ng) injected embryos included defective assembly of the PCV (arrow), absence of ISVs (arrowheads) and hypoplasia of the VVN (asterisk).
(B) Overexpression of VEGFA (1 ng mRNA) did not affect ISV formation (arrowheads) but caused hyperplasia of the VVN (asterisks). Note that the VVN defects
occur bilaterally. (C) Overexpression of VEGFA (1 ng mRNA) induces widespread, bilateral ectopic expression of apelin (asterisks) in the ventral belly (compare with
H, right panel). (D) Co-injection of VEGFA and apelin mRNA (0.5 ng each) results in VVN hyperplasia (asterisk) and premature outgrowth of ISVs (arrowheads).
(E) Double-knockdown of VEGFA and apelin results in vascular defects comparable to panel A. (F) Apelin mRNA (1 ng) fails to rescue vascular development in
VEGFA-MO (5 ng) injected embryos. The resulting embryos lack ISVs (arrowheads), have PCV defects (arrows) and display a hyperplastic VVN (asterisk).
(G) VEGFA mRNA (1 ng) fails to rescue the ISV defects in apelin-MO (5 ng) injected embryos. Embryos lack ISVs (arrowhead) and display bilateral VVN
hyperplasia (asterisk). (H) Injection of β-gal mRNA (1.25 ng) has no effect on vascular development and apelin expression. Note the lack of apelin expression
(asterisk) in the ventral belly.
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Table 2
Summary of vascular phenotypes of mRNA and MO-injected embryos









VVN defects Premature ISVs Loss of ISVs
VEGFA-MO 5 D2 70 a 0 91 23
VEGFA RNA 1 D2 89 b 0 0 65
VEGFA RNA and 0.5 D2 89 b 61 0 46
apelin RNA 0.5
VEGFA-MO and 5 D2 89 a 0 59 61
apelin RNA 1
VEGFA RNA 1 V2 94 b 7 0 118
Apelin-MO 5 V2 0 0 71 65
Apelin-MO and 5 V2 98 b 0 52 84
VEGFA RNA 1
MO and/or mRNA injections were performed unilaterally into single blastomeres of 8-cell stage embryos as indicated. The vascular phenotypes were scored in stage
32 embryos stained for expression of the vascular marker Erg. Each experiment was performed at least twice. Similar results were obtained with embryos stained with
the vascular markers VEGFR2 and APJ. VEGFA RNA and apelin RNA refer to VEGFAb168 and preproapelin mRNA injections, respectively. ISV, intersomitic vein;
MO, morpholino; VVN, vitelline vein network.
a Frequency of hypoplastic VVN.
b Frequency of hyperplastic VVN.
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co-injected VEGFA and preproapelin mRNA. The resulting
embryos displayed a combination of two gain-of-function phe-
notypes, namely (i) disorganized, hyperplastic VVNs and (ii)
premature ISV angiogenesis (Fig. 4D). Apelin and VEGFA
overexpression have therefore distinct effects on vascular deve-
lopment in Xenopus embryos. Interestingly, knocking down
both VEGFA and apelin resulted in a severe vasculogenesis
phenotype similar to VEGFA-MO-only-treated embryos (com-
pare Figs. 4A, E). We then asked whether injection of prepro-
apelin mRNA could rescue the vasculogenesis phenotype
observed in VEGFA knockdown embryos, which was how-
ever not the case (Figs. 4A, F). Finally, we found that VEGFA
did not restore ISV outgrowth in apelin knockdown embryos
(Fig. 4G). Collectively, VEGFA acts prior to apelin in ISV
angiogenesis.
Xenopus APJ mediates apelin signaling
We performed in vitro studies to address whether apelin-13
induces internalization of Xenopus APJ and activation of signa-
ling. Fusion of the enhanced version of green fluorescent pro-
tein (EGFP) to mammalian APJ proteins does not interfere withFig. 5. Apelin-13 activates signaling of Xenopus APJ and promotes chemotaxis of pr
apelin-13. Confocal images of DAPI (blue) stained CHO cells expressing Xenopus A
are shown. Scale bar, 10 μm. (B) Activation of Xenopus APJ signaling by apelin-13.
and the parental CHO (red) cell line in the presence of 0.2 mM IBMX and 1 μM forsk
of inhibition against maximum cAMP production by cells without apelin treatment.
apelin and APJ expression levels in primary endothelial cells analyzed by quantitat
expression levels are expressed as arbitrary units normalized to GAPDH, and are th
presence (+) or absence (−) of reverse transcriptase. (D) Cell proliferation assays perfo
72 h with the indicated polypeptides. Cell proliferation was measured using a MTS-b
percentage of increase of absorbance against control cells. The results are shown as the
ANOVA. (E) Induction of chemotaxis in HUVECs by apelin-13. Chemotactic respo
chemokine gradient against control cells without treatment. *P-value<0.001 vs. contr
and apelin treatment. Collagen-embedded HUVEC spheroids were incubated with VE
from at least 14 spheroids was quantified and is given as mean±S.D. Scale bars, 10receptor functions (Reaux et al., 2001; Zhou et al., 2003).
Therefore, a CHO cell line was established expressing a Xe-
nopus APJ-EGFP fusion protein and ligand-induced internali-
zation of Xenopus APJ was monitored by confocal fluorescence
microscopy. In the absence of apelin, APJ primarily localized to
the cell surface (Fig. 5A). After exposure to apelin-13, the
receptor was redistributed to the cytoplasm with distinct
perinuclear accumulation. In contrast, the localization of APJ
was not altered by addition of angiotensin II (not shown).
Apelin signaling inhibits forskolin-induced cAMP production,
which indicates that APJ couples to inhibitory G-proteins Gi
(Habata et al., 1999). Similarly, cAMP production was inhibited
in CHO cells expressing Xenopus APJ by apelin-13. The
inhibition was dose-dependent with a half-maximal inhibition
IC50 value of 45 (±15) nM (Fig. 5B). Taken together, our
findings demonstrate that Xenopus APJ is a genuine receptor
for apelin-13.
Apelin elicits a chemotactic response in primary human
endothelial cells
It previously has been reported that apelin stimulates proli-
feration and migration of RF/6A cells, a rhesus macaqueimary human endothelial cells. (A) Induction of Xenopus APJ internalization by
PJ-EGFP (green) before (control) and 30 min after addition of 100 nM apelin-13
Dose–response curves of the inhibition of cAMP production in CHO-APJ (blue)
olin are shown. The inhibition of cAMP production is indicated as the percentage
The values represent mean (±S.D.) of triplicate assays. (C) Comparison of the
ive real-time PCR (upper panel) and RT-PCR (lower panel). Upper panel: The
e mean (±S.D.) of triplicates. Lower panel: RT-PCR analysis was performed in
rmed with HUVECs in presence of different factors. The cells were incubated for
ased colorimetric assay. The obtained proliferative responses are represented as
mean (±S.D.) of 6 biological replicates. *P-value<0.01 vs. control by one-way
nses are indicated as the increase in percentage of cells migrating towards the
ol by one-way ANOVA. (F) Endothelial spheroid vessel outgrowth after VEGFA
GFA (10 ng/ml; 0.5 nM) or apelin-13 (100 nM) for 48 h. The number of sprouts
0 μm.
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However, RF/6A cells are spontaneously immortalized cells and
may therefore differ from primary endothelial cells in their res-
ponses to apelin. Hence, we tested primary human endothelial
cells for expression of apelin and APJ. For human umbilicalvein endothelial cells (HUVEC), expression of apelin has been
previously demonstrated (Kasai et al., 2004); however, it is still
a matter of debate whether HUVECs express APJ constitutively
(Kasai et al., 2004; Masri et al., 2004). We tested HUVEC and
human umbilical arterial endothelial cells (HUAEC) by
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expression of apelin and APJ. Interestingly, the relative expres-
sion levels of APJ and apelin were 3- and 5-fold, respectively, in
HUVECs over HUAECs. Finally, we also assessed human
dermal microvascular endothelial cells (HMVEC-D). Here,
quantitative PCR revealed apelin and APJ expression at levels
similar to HUVECs and HUAECs, respectively (not shown).
Since HUVECs expressed highest levels of APJ mRNA, they
were used in all subsequent cell-based assays.
The proliferative response of serum-starved HUVECs to
apelin treatment was compared to VEGFA165 and basic FGF
(bFGF), two potent endothelial cell mitogens (Esch et al., 1985;
Keck et al., 1989; Leung et al., 1989). As expected, treatment of
HUVECs with VEGFA165 or bFGF within 72 h caused a robust
mitogenic response. In contrast, apelin-13 (0.1 to 100 nM were
tested) neither induced significant proliferation of HUVECs nor
did it cause detectable cell death (Fig. 5D). Similar results were
obtained with HUAECs and HMVEC-Ds (not shown). We
therefore conclude that primary human endothelial cells, unlike
immortalized endothelial cells, do not show a significant proli-
ferative response to apelin-13.
Next, we determined whether apelin-13 may confer chemo-
attraction to primary endothelial cells. As shown in Fig. 5E,
stimulation with apelin-13 led to a 40% increase in directed
migration of HUVECs across semi-permeable membrane sup-
ports. Consistent with a previous study (Desideri et al., 2003),
angiotensin II did not promote HUVEC migration. The en-
hancement of cell migration by apelin was comparable to bFGF
treatment but not as pronounced as with VEGFA. Finally, we
utilized an endothelial cell spheroid assay (Korff and Augustin,
1998; Korff and Augustin, 1999) to assess whether apelin-13 is
sufficient to promote angiogenic sprouting in vitro. While
VEGFA supported robust radial sprouting, apelin-13 treatment
failed to induce discernible effects with HUVEC, HUAEC, and
HMVEC-D spheroids (Fig. 5F; not shown). Moreover, no sy-
nergistic activities were detected, when spheroids were treated
both with VEGFA and apelin-13 (not shown). In summary,
these results suggest that apelin-13 has no apparent mitogenic
activity on primary human endothelial cells nor is it able to
induce angiogenic sprouting of spheroid cultures by itself.
Apelin-13 acts, however, as a potent chemotactic factor for
human endothelial cells.
Discussion
In the present study, we examined the role of the GPCR APJ
and its ligand apelin in embryonic and pathologic angiogenesis.
Two recent studies have reported contradicting findings on the
role of apelin signaling during blood vessel development in
Xenopus (Cox et al., 2006; Inui et al., 2006). Here we show
that apelin-APJ signaling is required for embryonic angiogen-
esis in Xenopus. Furthermore, apelin is sufficient to induce a
robust angiogenic response in vivo. These findings confirm and
extend the recent study of Cox et al. (2006). We also show that
apelin acts both via paracrine as well as autocrine mechanisms
to promote angiogenesis in vivo. Moreover, we demonstrate
here that apelin functions as a chemoattractant rather than amitogen on primary human endothelial cells. Finally, we pro-
vide first evidence linking apelin-APJ signaling to tumor angio-
genesis in human neoplasms.
Evolutionary conservation of vertebrate apelin proteins
Proteolytic maturation of preproapelin generates the apelin-
36, apelin-17, and apelin-13 peptides, where apelin-13 repre-
sents the most active isoform (Hosoya et al., 2000; Tatemoto et
al., 1998). Since apelin-13 is sufficient to induce full activation
of APJ signaling, the physiological significance of the longer
isoforms has been unclear. Interestingly, cloning of the Xeno-
pus apelin gene revealed that the mature apelin-13 peptide has
remained invariant during 360 million years of tetrapod
evolution, while the longer apelin-17 and apelin-36 peptides
differ considerably. The invariant amino acid residues shared
by the longer forms are confined to the predicted proteolytic
cleavage sites. Apelin-13 therefore represents the primary,
physiologically important protein product of the apelin gene.
Given the lack of evolutionary conservation, apelin-36 may
function as a precursor with some biological activity until
undergoing further proteolysis to yield the fully active apelin-
13 peptide.
Apelin expression is confined to areas of embryonic
angiogenesis
Earlier studies have shown that APJ is expressed in blood
vessels of the developing mouse and Xenopus embryo (Devic et
al., 1996; Devic et al., 1999). Here, we show that the expression
patterns of the APJ ligand apelin are conserved between mouse
and Xenopus. Apelin expression occurred either in close vicinity
to APJ or was coexpressed with APJ in endothelia. Strikingly,
apelin expression preceded the onset of ISV growth—a finding
previously not reported by others. First, cells of the dermatome
flanking the intersomitic space initiate apelin expression. Once
the ISV has sprouted, apelin and APJ are coexpressed in the
extending intersomitic capillary. Hence, paracrine signaling of
apelin acts initially on the newly forming ISV, while subsequent
autocrine apelin signaling may sustain extension of ISVs.
Autocrine apelin signaling has also been reported in the leading
edge of retinal vessels in mice (Saint-Geniez et al., 2002).
Furthermore, our data on coexpression of apelin and APJ in
different primary human endothelial cell types also implies au-
tocrine signalling activities. Remarkably, both modes of signa-
ling may also operate during tumor angiogenesis (see below)
suggesting a general flexibility of apelin signaling mechanisms
in vivo.
Apelin signaling is necessary and sufficient to trigger
embryonic angiogenesis
Contradicting findings regarding the role of apelin signaling
during Xenopus embryogenesis have been recently reported
(Cox et al., 2006; Inui et al., 2006). The loss-of-function studies
reported here fully support and extend the observations of Cox
et al. (2006). Knockdown of apelin in Xenopus embryos
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Moreover, disruption of APJ function impaired ISV formation
without causing discernable phenotypes during earlier stages of
vascular development. Hence, despite widespread expression
during vasculogenesis, endothelial APJ functions are only es-
sential during sprouting angiogenesis in areas that express
apelin. In the mouse, APJ has recently been implicated in blood
pressure control; however, APJ-deficiency resulted in no ob-
vious defects in vascular development (Ishida et al., 2004). The
apparent differences in the requirement for APJ function in
vascular development between Xenopus and mice may indicate
redundancy of apelin receptors in higher vertebrates. In an APJ-
deficient background, mice may be able to use APJ-related
GPCRs, such as AT1R, to mediate apelin signal during angio-
genesis. In Xenopus, we failed to detect any expression of
AT1R or the related AT2R gene during ISV angiogenesis (V.
Dabouras and A. W. Brändli, unpublished observations).
The study of Inui et al. (2006) suggests a much more general
role for apelin signaling in cardiovascular development and
differentiation, which is not supported by Cox et al. (2006) and
our work. We do not know the precise reasons for these discre-
pancies. In our knockdown studies, we failed to detect any
evidence for abnormalities in the differentiation of endothelia,
erythrocytes, and pronephric epithelia (see Supplementary Fig.
6). Inui et al. injected typically MO doses ranging from 20 to
40 ng, which exceeds our standard 5-ng doses by up to 8-fold.
Finally, the apelin-MO used by Inui et al. to target the 5′-UTR
of apelin perfectly matches apelin-a but harbors 4 mismatches
over the 19 nucleotides that align with the known apelin-b
nucleotide sequence (GenBank Acc. No. DQ471853). This may
explain why the authors had to inject larger amounts of the
apelin-MO to induce a knockdown phenotype in Xenopus
embryos. The widespread cardiovascular defects reported by
Inui et al.may therefore be caused by off-target effects resulting
from injections of exceedingly high doses of MOs.
The angiogenic potential of apelin has recently been docu-
mented by different implantation assays, which include Matri-
gel plug assays in the mouse, chicken chorioallantoic membrane
(CAM) assays, and bead—as well as cell implantation experi-
ments in Xenopus embryos (Cox et al., 2006; Kasai et al.,
2004). We provide here novel evidence for the angiogenic po-
tential of apelin in vivo. Apelin expression occurs in a spatially
and temporally regulated manner along the anteroposterior axis
preceding the initiation of ISV growth. While ectopic apelin
expression resulted in premature angiogenic growth of ISVs,
VEGFA overexpression failed to elicit a similar response. Our
findings therefore imply that VEGFA and apelin fulfill distinct
functions in ISV angiogenesis. Most importantly, expression of
apelin appears to be the critical event triggering ISVoutgrowth.
Taken together, the evidence provided here clearly demonstrates
that apelin acts as a potent pro-angiogenic factor in vivo.
Apelin has chemotactic properties on primary endothelial cells
Angiogenesis is characterized by a complex cascade of
events during which the quiescent endothelial cells of a blood
vessel become activated to proteolytically degrade their under-lying extracellular matrix, directionally migrate towards angio-
genic stimuli, proliferate, and form new capillary networks
(Carmeliet, 2000). Given its angiogenic properties in vivo, the
question arises which of these cellular programs are directly
controlled by apelin. We and others (Cox et al., 2006; Kasai et
al., 2004) have explored the effects of apelin treatment on cul-
tured endothelial cells and obtained partially conflicting results.
The most striking differences relate to the mitogenic potential of
apelin.
Treatment of apelin promotes cell proliferation of immorta-
lized endothelial cell lines (Cox et al., 2006; Kasai et al., 2004).
To reassess the potential mitogenic activity of apelin, we tried to
mimic the in vivo situation by utilizing human primary
endothelial cell preparations (HUVEC, HUAEC, and
HMVEC-D) rather than immortalized endothelial cells. Our
analysis of early-passage primary endothelial cell preparations
revealed that all cells expressed APJ transcripts. Interestingly,
immunocytochemical studies have provided independent evi-
dence for APJ expression in HUVECs (Kleinz et al., 2005). We
tested a wide range of apelin-13 concentrations in the presence
of minimal medium but failed to detect any significant
proliferative responses. We therefore conclude that apelin has
no profound mitogenic activity on primary human endothelial
cells.
First evidence indicating a role of apelin signaling in
stimulating cell migration was obtained with APJ-transfected
cell lines (Hashimoto et al., 2005; Hosoya et al., 2000). More
recently, chemotactic responses of immortalized endothelial
cells to apelin treatment were reported (Cox et al., 2006; Kasai
et al., 2004). We have now extended these observations to
primary human endothelial cells by demonstrating that apelin
induced migration of HUVECs in culture. Interestingly,
VEGFA readily induced capillary-like sprouting of endothelial
spheroids in vitro but apelin failed to do so. This suggests that
apelin is not sufficient to trigger all necessary steps of angio-
genic sprouting in vitro. Apelin primarily act as a chemotactic
factor on endothelial cells promoting endothelial cell migration.
Distinct roles for VEGFA and apelin in intersomitic vein
angiogenesis
VEGFA is a major regulator of blood vessel formation and
function (Ferrara et al., 2003). It coordinately controls proli-
feration, survival, and migration of endothelial cells during
blood vessel development. As shown here, VEGFA knockdown
experiments in Xenopus resulted in severe vascular abnormal-
ities including defects in PCV assembly, development of an
immature, hypoplastic VVN, and absence of ISVs. ISV forma-
tion in Xenopus is, however, not only dependent on VEGFA but
also requires apelin signaling. This raises the question of how
VEGFA and apelin cooperate in ISV formation. Our studies
provide a first glimpse into the possible mechanisms. Knock-
down of VEGFA function did neither affect vascular expression
of APJ nor did it interfere with expression of apelin in the
dermatome. Ectopic expression of VEGFA is, however, suffi-
cient to induce apelin expression in the VVN. Noteworthy,
placental growth factor (PlGF, PGF), a VEGF family member,
Fig. 6. Model depicting the relationship of apelin and VEGFA signaling during
angiogenesis of ISVs in Xenopus. The PCV and three somites (S) are shown in
lateral view with anterior to the left and dorsal to the top. (A) Prior to the
initiation of ISV growth, all somites along the anterioposterior axis express
VEGFA. Furthermore, the PCV expresses VEGFRs and APJ and, thus, is com-
petent to respond to VEGFA and apelin, respectively. Paracrine VEGFA sig-
naling primes the PCV for angiogenic sprouting. (B) Apelin expression in
dermatomal cell populations flanking the 1st intersomitic space has been
initiated and precedes sprouting of the first ISV. (C) Paracrine apelin signaling
has triggered sprouting of the ISV. Dermatomal apelin expression spreads
dorsally ahead of the ISV growth. Furthermore, apelin expression in the
dermatome flanking the 2nd intersomitic space has been initiated. (D) ISV
endothelia at the leading edge start to express apelin. Apelin signaling acts now
in an autocrine manner to sustain endothelial cell migration. Angiogenic growth
of the second ISV is initiated and apelin expression is induced in the dermatome
flanking the neighboring, more posterior intersomitic space.
612 R.E. Kälin et al. / Developmental Biology 305 (2007) 599–614has been reported to induce apelin expression in primary capil-
lary endothelial cells (Autiero et al., 2003). Collectively, these
findings implicate VEGFs as inducers of apelin expression in
endothelial cells.
Our studies of VEGFA and apelin function suggest a mole-
cular pathway for ISV development in Xenopus (Fig. 6). Ini-
tially, somitic VEGFA signals act along the entire antero-
posterior axis on the adjacent endothelia of the PCV to initiate
the necessary molecular and cellular processes for angiogenic
sprouting. Subsequently, paracrine apelin signaling originating
from dermatomal cells of the somites triggers the stage-depen-
dent outgrowth of individual intersomitic vessels along the
anteroposterior axis. Similar to retinal angiogenesis (Gerhardt et
al., 2003), somitic paracrine VEGFA signaling may now serve
two distinct functions: in distal endothelial cells of the inter-
somitic vessel VEGFA may induce a proliferative response,
whereas at the leading edge VEGFA possibly guides cell mi-
gration. Autocrine apelin signaling may subsequently stimulate
motility of endothelial cells at the leading edge. Finally,
repulsive Eph receptor signaling restricts angiogenic growth
to the intersomitic spaces as previously demonstrated (Helbling
et al., 2000).
Apelin signaling in tumor angiogenesis
The marked induction of angiogenesis in GBMs (Yao et al.,
2001) suggests that pathological vessel formation is required for
tumor progression. In normal brain tissue, no apelin and only
trace amounts of APJ were detectable in meningeal and intra-
parenchymal blood vessels. By contrast, we consistently found
a dramatic upregulation of apelin and APJ expression within
GBM-associated microvascular proliferations, particularly in
areas of vessel sprouting and branching. Coexpression of ligand
and receptor in the angiogenic tumor vasculature is consistent
with an autocrine mode of signaling, similar to the develop-
mental regulation of apelin and APJ. Apelin expression was also
detectable in radially oriented tumor cells surrounding band-like
necrotic foci—a finding which may indicate that apelin, like
VEGFA (Plate et al., 1992), is hypoxia-inducible in vivo. This
notion is supported by recent studies in cultured cells (Cox et
al., 2006). Coexpression of apelin and VEGFA in tumor cells is
reminiscent of the angiogenic growth of intersomitic vessels,
and thus suggests a similar paracrine function of VEGFA/apelin
in tumor angiogenesis.
Clinical significance and therapeutic implications
To date, a limited number of clinical anti-angiogenesis trials
utilizing small molecule inhibitors to VEGFA signaling have
been performed to treat GBM. However, none of them has
yielded a significant clinical benefit (Sun et al., 2006). It appears
that tumors evade anti-VEGFA treatment by upregulating addi-
tional angiogenic factors. Interestingly, stem cell factor (SCF)
was recently discovered as a potent angiogenic factor over-
expressed in GBM biopsies (Sun et al., 2006). The consistent
upregulation of apelin and APJ expression in GBM reported
here introduces now an additional angiogenic signaling path-way. It is therefore likely that apelin, SCF, and VEGFA syner-
gize in promoting angiogenic responses in malignant gliomas
and complete inhibition of tumor angiogenesis may require si-
multaneous disruption of all three signaling pathways. The
apelin-APJ signal transduction pathway seems particularly
613R.E. Kälin et al. / Developmental Biology 305 (2007) 599–614attractive for the development of small-molecule drugs given
that APJ encodes a GPCR and thus represents a “drugable”
target. In addition, disruption of apelin signaling in Xenopus
blocks angiogenic blood vessel growth without altering preexis-
ting and matured vasculature. Finally, functional screening and
preclinical validation of drug candidates can, at least to some
extent, be performed in Xenopus tadpoles (Brändli, 2004).
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